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Mutations in superoxide dismutase (SOD1) cause
amyotrophic lateral sclerosis (ALS), a neurodegener-
ative disease characterized by loss of motor neurons
and accompanied by accumulation of misfolded
SOD1 onto the cytoplasmic faces of intracellular
organelles, including mitochondria and the endo-
plasmic reticulum (ER). Using inhibition of misfolded
SOD1 deposition onto mitochondria as an assay, a
chaperone activity abundant in nonneuronal tissues
is now purified and identified to be the multifunc-
tional macrophage migration inhibitory factor (MIF),
whose activities include an ATP-independent protein
folding chaperone. Purified MIF is shown to directly
inhibit mutant SOD1 misfolding. Elevating MIF in
neuronal cells suppresses accumulation of mis-
folded SOD1 and its association with mitochondria
and the ER and extends survival of mutant SOD1-ex-
pressing motor neurons. Accumulated MIF protein is
identified to be low in motor neurons, implicating
correspondingly low chaperone activity as a compo-
nent of vulnerability to mutant SOD1 misfolding and
supporting therapies to enhance intracellular MIF
chaperone activity.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive adult-onset
neurodegenerative disorder characterized by the selective loss218 Neuron 86, 218–232, April 8, 2015 ª2015 Elsevier Inc.of upper and lower motor neurons. About 10% are inherited in
a dominant manner (Da Cruz and Cleveland, 2011), with 20%
of familial cases caused by mutation of cytoplasmic Cu/Zn su-
peroxide dismutase (SOD1) (Rosen et al., 1993). The exact
mechanism(s) responsible for motor neuron degeneration re-
mains unsettled, albeit models for each of the nine most promi-
nently proposed pathways include damage from misfolded,
mutant SOD1 (Ilieva et al., 2009).
Multiple groups have identified that SOD1 mutants with diver-
gent biochemical characteristics share a common property,
with a proportion of the predominantly cytosolic SOD1 being
localized to mitochondria (Israelson et al., 2010; Liu et al.,
2004; Mattiazzi et al., 2002; Vande Velde et al., 2008) and/or
the ER (Fujisawa et al., 2012; Nishitoh et al., 2008) but only in
nervous system tissues in patient samples and rodent models.
In particular, misfolded mutant SOD1 association with derlin-1,
a component of the ER-associated degradation pathway, has
been implicated in induction of ER stress from disrupted
removal of misfolded proteins from the ER (Fujisawa et al.,
2012; Nishitoh et al., 2008). Derlin-1 is bound by at least 132
of the ALS-linked SOD1 mutants, each of which exposes a
derlin-1-binding domain buried in correctly folded SOD1 (Fuji-
sawa et al., 2012).
Purification of mitochondria, including floatation steps that
eliminate protein-only aggregates, has demonstrated that
mutant SOD1 deposition occurs on the cytoplasmic face of the
outer membrane of spinal cord mitochondria (Liu et al., 2004;
Vande Velde et al., 2008), accompanied by alteredmitochondrial
shape and distribution (Vande Velde et al., 2011). These findings
were reinforced by demonstration (using sensitivity to proteoly-
sis and immunoprecipitation with an antibody specific for mis-
folded SOD1) that misfolded forms of both dismutase active
and inactive mutant SOD1 are deposited onto the cytoplasmic
AB C D
Figure 1. The Cytosol Determines Mutant SOD1 Association with Mitochondria
(A) Schematic outlining purification steps for isolation of microsomes, cytosol, and mitochondria from liver or spinal cord.
(B) Immunoblot assay for mutant SOD1 associated with microsomes or mitochondria purified as in (A) from SOD1G93A rat spinal cord. Calnexin and cytochrome c
immunoblots were used as specific markers for microsomal and mitochondrial fractions, respectively.
(C) Cytosol from SOD1G93A- or SOD1H46R-expressing rats was incubated with nontransgenic spinal cord- or liver-derived mitochondria, and the mitochondria
were recovered and analyzed by immunoblotting for bound mutant SOD1. Immunoblotting for VDAC1 was used to verify numbers of mitochondria recovered
from each assay. Bottom: input cytosols were immunoblotted to identify the initial levels of human mutant SOD1 and endogenous rat SOD1.
(D) Recombinantmutant SOD1G85Rwas incubated with nontransgenic liver mitochondria in the absence or presence of liver or spinal cord cytosol fromSOD1G93A
rats. Mitochondria were recovered and assayed by immunoblotting for whether addition of spinal cord or liver cytosol affected recruitment of SOD1G85R to
mitochondria. Mitochondrial recovery was assessed by immunoblotting for VDAC1 or cytochrome c. The two lanes from the right panel were not loaded in the
same order as shown.face of the outer membrane of spinal cord mitochondria (Vande
Velde et al., 2008). One component directly bound by misfolded
SOD1 is voltage-dependent anion channel-1 (VDAC1), with bind-
ing inhibiting its conductance of adenine nucleotides across the
outermitochondrial membrane (Israelson et al., 2010).Moreover,
mutant SOD1 may also interact with other components of the
mitochondrial outer membrane, including Bcl-2 (Pedrini et al.,
2010) and the protein import machinery (Li et al., 2010), thereby
altering the corresponding activities.
Recognizing that expression of SOD1 is ubiquitous but mis-
folded SOD1 accumulation and binding to mitochondria and
the ER are found only in nervous system tissues, one of the
most important unsolved questions is the molecular mecha-
nism(s) underlying cell-type selectivity for accumulation of mis-
folded SOD1 and its association with intracellular organelles.
Here we purify a cytosolic activity whose action inhibits mutant
SOD1 misfolding onto mitochondria and the ER. We identify
this factor to be macrophage migration inhibitory factor (MIF),
a multifunctional protein whose activities include an ATP-inde-
pendent protein folding chaperone (Cherepkova et al., 2006).
We propose that a low MIF level within motor neurons is onecomponent of their selective vulnerability to ubiquitously ex-
pressed mutations in SOD1.
RESULTS
The Cytosol Determines Mutant SOD1 Association with
Mitochondria and the ER
We previously reported that ALS-causing mutant SOD1 associ-
ation with mitochondria was characterized by misfolded SOD1
binding to components, including VDAC1, on the outer mito-
chondrial membrane but was found for mitochondria isolated
from spinal cord but not for those similarly purified from liver
(Israelson et al., 2010). Consistent with this and other reports,
immunoblot analysis of microsomes or mitochondria isolated
from spinal cord homogenates (see schematic in Figure 1A)
from rats expressing either of two ALS-linked mutations in
SOD1 (SOD1G93A [Howland et al., 2002] and SOD1H46R [Nagai
et al., 2001]) revealed that mutant SOD1 bound both to micro-
somal and mitochondrial membranes (Figure 1B). To determine
whether this selective association of mutant SOD1 with spinal
mitochondria was mediated by the spinal cord mitochondria orNeuron 86, 218–232, April 8, 2015 ª2015 Elsevier Inc. 219
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Figure 2. Identification of MIF as Having an
Activity that Can Suppress Mutant SOD1
Association with Mitochondria
(A) Schematic outlining the purification steps of an
activity in liver cytosol that inhibits mutant SOD1
association with normal mitochondria, followed by
mass spectrometry to identify remaining proteins.
(B) Coomassie staining of an SDS-polyacrylamide
gel of gel filtration fractions from (A).
(C) Assay of gel filtration fractions from (A) and (B)
for the presence of an activity that inhibits asso-
ciation of recombinant mutant SOD1G85R with
normal liver mitochondria.
(D) The seven proteins identified by mass spec-
trometry to be present within gel filtration fraction
41 from (C), which contained activity inhibiting
recombinant SOD1 binding to nontransgenic
liver mitochondria and had the simplest protein
composition.
(E) Immunoblotting of gel filtration fractions for the
presence of each of the seven candidate proteins
identified in (D). Only MIF cofractionated with
inhibitory activity. SC, spinal cord; L, liver.the corresponding cytosol, we isolated normal, nontransgenic
mitochondria from spinal cord and liver. Those mitochondria
were then incubated (Figure 1C) with cytosolic extracts prepared
(as in Figure 1A) from spinal cords or livers of rats expressing dis-
mutase active (SOD1G93A) or inactive (SOD1H46R) mutants.
The mitochondria were reisolated and analyzed by immuno-
blotting for mutant SOD1. Although the liver and spinal cord cy-
tosols contained comparable levels of mutant human SOD1 (Fig-
ure 1C, bottom), none of the mutant SOD1 in liver cytosol bound
to liver- or spinal cord-derived nontransgenic mitochondria. In
contrast, incubation with spinal cord cytosols from SOD1G93A-
or SOD1H46R-expressing rats did yield association of a propor-
tion of both mutant SOD1s with wild-type mitochondria. For
both dismutase active (SOD1G93A) and inactive (SOD1H46R) mu-
tants, binding was independent of the tissue from which the
mitochondria were isolated (Figure 1C). Thus, the tissue origin
of the cytosol, not of the mitochondrion, determines whether
mutant SOD1 in those cytosols binds to mitochondria.220 Neuron 86, 218–232, April 8, 2015 ª2015 Elsevier Inc.Next, we investigated whether there
was a factor(s) in spinal cord cytosol that
induced association of SOD1 with normal
mitochondria or, in contrast, whether
some factor in the liver prevented binding.
To do this, recombinant SOD1G85R was
incubated with mitochondria purified
from liver of nontransgenic rats in the
presence of SOD1G93A spinal cord or liver
extract. Whereas spinal cord cytosol did
not affect SOD1G85R association with
mitochondria (Figure 1D, lane 5), added
liver cytosol inhibited it (Figure 1D,
compare lanes 1 and 2). This inhibitory
activity was not affected by inhibitors of
the Hsp70 and Hsp90 protein chaperones
and was independent of calcium (Fig-ure S1). Remarkably, although the inhibitory activity was heat
labile (consistent with a protein activity), it was not inactivated
by degradation of most proteins by incubation of the liver cytosol
with proteinase K (Figure 1D, lane 3).
Identification of MIF as an Inhibitor of Mutant SOD1
Association with Mitochondria
To identify the activity responsible for blocking association of
mutant SOD1 with mitochondria, liver cytosol was incubated
with proteinase K and the resultant peptides and other low-
molecular-weight species below 10 kDa were removed by cen-
trifugal filtration. Remaining proteins and other macromolecules
were then fractionated by gel permeation chromatography (see
schematic in Figure 2A). Finally, fractions were assayed for the
ability to inhibit recombinant SOD1G85R binding to nontransgenic
mitochondria. Activity eluted broadly with apparent molecular
weights between 12 and 45 kDa. Proteins in the fractions with
activity (fractions 23–41; Figure 2C) were visualized by PAGE
and Coomassie staining (Figure 2B). The most slowly eluting
fraction with activity (fraction 41) had only a handful of observ-
able polypeptides (Figure 2B). We therefore used mass spec-
trometry to analyze its protein content. Although the sensitivity
of mass spectrometry frequently identifies many proteins pre-
sent in such assays, remarkably, however, only seven proteins
were detected (Figure 2D). One of these, profilin-1, an actin-
binding protein linked to regulation of actin polymerization,
was notable, asmutations in it are causative of a small proportion
of inherited ALS (Wu et al., 2012). Nevertheless, immunoblotting
was used to determine that profilin-1 was absent from many
fractions (23–30) that retained inhibitory activity (Figure 2E).
Similar immunoblotting with antibodies to each of the six re-
maining proteins determined that only one cofractionated with
the inhibitory activity (Figure 2E). This was the 12-kDa macro-
phage migration inhibitory factor, which has previously been
implicated in divergent functional roles: as a protein folding
chaperone (Cherepkova et al., 2006), thiol-oxidoreductase pro-
tein (Kleemann et al., 1998), and secreted cytokine with an
important role in innate immunity (Calandra and Roger, 2003;
Lolis and Bucala, 2003). MIF eluted broadly in fractions spanning
from 12 to 45 kDa apparent molecular weights, just as did the ac-
tivity for inhibiting mutant SOD1 binding to mitochondria. The
broad elution of MIF was not because of poor resolution of the
column, as other proteins (including alcohol dehydrogenase,
profilin-1, and SOD1 itself) fractionated much more sharply.
Rather, the broad elution was fully consistent with MIF’s known
ability to form dimers and trimers (Mischke et al., 1998; Philo
et al., 2004) through an exposed hydrophobic face as a part of
its ATP-independent activity as a protein folding chaperone
(Cherepkova et al., 2006). Interestingly, MIF protein levels do
not change within the spinal cord during disease course in
SOD1 mutant mice (Figure S2).
Dose-Dependent Inhibition by MIF of Mutant SOD1
Association with Mitochondria
As a direct test of whether MIF inhibits association of mutant
SOD1 with mitochondria, purified mutant or wild-type SOD1
(Figure 3A, bottom right) was added to normal liver mitochondria
in the presence or absence of purifiedMIF (see schematic in Fig-
ure 3A). After recovering the mitochondria by centrifugation,
immunoblotting was used to reveal that a proportion of
SOD1G93A and SOD1G85R, but not SOD1WT, bound to nontrans-
genic mitochondria in a dose-dependent manner (Figure S3) in
the absence of MIF (Figure 3B). Mutant SOD1 binding was in-
hibited in a dose-dependent manner by coincubation with MIF,
with a 1:80 molar ratio of MIF to SOD1 (50 ng of MIF and 4 mg
of mutant SOD1), sufficient to strongly diminish (by >90%) bind-
ing of mutant SOD1 to mitochondria (Figure 3C). Importantly,
about 5%–10% of recombinant mutant SOD1 bound to mito-
chondria in these assays (Figure 3C), a percentage of misfolded
SOD1 similar to that measured in immunoprecipitates of the
initial recombinant SOD1 preparation when using B8H10 anti-
bodies that bind misfolded SOD1 (Figure S5).
We exploited the known proteinase K resistance or sensitivity,
respectively, of correctly folded and misfolded SOD1G93A
(Borchelt et al., 1994; Ratovitski et al., 1999) to test whether
the mutant SOD1 that associates with mitochondria representsthe initially misfolded fraction. We initially verified that most
of the dismutase active SOD1G93A is protease resistant; in
contrast, most of the inactive SOD1G85R was sensitive (Fig-
ure 3E). SOD1G93A was preincubated with proteinase K, the pro-
tease was then inactivated by addition of PMSF and the mixture
was incubated with normal liver mitochondria, and finally mito-
chondria along with any bound mutant SOD1 were recovered
by centrifugation. Immunoblotting for human SOD1 demon-
strated that SOD1G93A association with mitochondria was
completely eliminated by proteinase K preincubation, confirming
that the protease-sensitive, misfolded fraction is the one that
associates with mitochondria (Figure 3D).
Inhibition of misfolded SOD1 association with mitochondria
was specific to MIF, as other chaperones tested, including
Hsp27, Hsc70, aB-crystallin (previously reported to interact
with mutant and misfolded SOD1 and modulate its aggregation;
Karch and Borchelt, 2010; Krishnan et al., 2008; Wang et al.,
2005, 2009; Yerbury et al., 2013; Zetterstro¨m et al., 2011b),
cyclophilin-A (one of our seven candidate proteins and previ-
ously proposed to act as a chaperone; Freskga˚rd et al.,
1992), or glutathione peroxidase (a protein with thiol-oxidore-
ductase activity, an activity that has been proposed to be
crucial for the association of mutant SOD1 proteins with mito-
chondria; Cozzolino et al., 2008; Ferri et al., 2006), had no effect
on mutant SOD1 association with normal mitochondria (Figures
3F and 3G).
MIF Suppresses Misfolded Mutant SOD1 Association
with ER and Mitochondrial Membranes in Motor
Neuron-like Cells
We next tested whether MIF inhibited association of mutant
SOD1 not only with mitochondria but also with other intracellular
membranes in motor neuron-like (NSC-34) cells expressing
ALS-linked SOD1 mutants (see schematic in Figure 4A). EGFP-
tagged SOD1G93A or SOD1G85R was expressed by DNA trans-
fection, along with lower or higher amounts of MIF. Accumulated
levels were validated by immunoblotting for each protein (Fig-
ure 4B, bottom), and the association of mutant SOD1 with ER
membranes was determined after isolation of microsomes.
Both dismutase active (SOD1G93A) and dismutase inactive
(SOD1G85R) mutants bound to ER membranes in the presence
of the low endogenous levels of MIF (Figure 4B, lanes 1 and 4),
but binding in both cases was reduced in a dose-dependent
manner when MIF levels were elevated (Figure 4B). MIF also in-
hibited mutant SOD1 association with mitochondria (Figure 4C).
We next tested whether MIF also inhibited accumulation of
misfolded SOD1 in a dose-dependent manner in the samemotor
neuron-like cells expressing ALS-linked SOD1 mutants (see
schematic in Figure 4D). In the absence of transfected MIF, mis-
folded SOD1 accumulated and could be detected by immuno-
precipitation with the B8H10 antibody, which does not recognize
wild-type SOD1 but does recognize a wide spectrum of mis-
folded SOD1 mutants (Gros-Louis et al., 2010) including
SOD1G93A and SOD1G85R (Figure 4E, lanes 2 and 3). Transfection
to simultaneously express MIF along with either SOD1G93A or
SOD1G85R reduced the level of misfolded SOD1 (Figure 4E, lanes
4 and 5), without affecting the overall level of accumulated
mutant SOD1. Similar results were observed by expressingNeuron 86, 218–232, April 8, 2015 ª2015 Elsevier Inc. 221
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Figure 3. Recombinant MIF Inhibits Association of Mutant SOD1 with Mitochondria in a Dose-Dependent Manner
(A) Schematic of a protocol to test whether purified recombinant MIF inhibits association of recombinant SOD1G85R or SOD1G93A with normal liver mitochondria.
Lower right: Coomassie-stained SDS-polyacrylamide gel analysis of recombinant SOD1 and MIF.
(B) Immunoblotting of mitochondria recovered from the protocol in (A) and assayed for MIF-dependent inhibition of association of either SOD1G85R or SOD1G93A
when coincubatedwith nontransgenic livermitochondria. Immunoblotting for VDAC1was used to verify the amount ofmitochondria added/recovered. Bar values
represent the means ± SEM of three independent experiments.
(C) Immunoblot assay as in (A) for dose-dependent inhibition by recombinant MIF of mutant SOD1G85R binding to nontransgenic liver mitochondria. Immuno-
blotting for VDAC1 was used to determine mitochondrial recovery. Immunoblotting for MIF was used to determine the absence of MIF in the mitochondrial
fraction and the increased levels of MIF in the supernatant that were used.
(D) Immunoblotting of mitochondria recovered from the protocol in (A) and assayed for proteinase K-dependent inhibition of association of SOD1G93A with
nontransgenic liver mitochondria. Immunoblotting for VDAC1 was used to verify the amount of mitochondria added/recovered.
(E) Immunoblotting was used to determine the effect of proteinase K on recombinant SOD1G93A or SOD1G85R.
(F and G) Assay patterned after the protocol in (A) testing for whether purified (F) MIF, Hsp27, cyclophilin-A (Cyp-A), or glutathione peroxidase (Gprx) or (G) Hsc70
or aB-crystallin inhibits SOD1G85R association with nontransgenic liver mitochondria. Some lanes were not loaded in the same order as shown in the figure.MIF in the presence of untagged versions of SOD1G93A or
SOD1G85R in human SH-SY5Y neuroblastoma cells (Figure S4).
The Thiol-Oxidoreductase Activity of MIF Is Not
Necessary for Suppressing Misfolded SOD1
One of MIF’s previously documented enzymatic roles is as a
thiol-oxidoreductase (Kleemann et al., 1998). SOD1 monomers
lacking the C57-C146 disulfide bond represent the major portion
of misfolded SOD1 (Zetterstro¨m et al., 2013), thus suggesting
that a thiol-oxidoreductase activity may play an important role
in misfolded protein formation. To determine whether the action222 Neuron 86, 218–232, April 8, 2015 ª2015 Elsevier Inc.of MIF in suppressing accumulation of misfolded SOD1 required
this activity, cells were transfected with a point mutant of MIF
(MIFC60S) previously shown to completely lack oxidoreductase
activity (Kleemann et al., 1998). Coexpression of MIFC60S in
NSC-34 cells with either SOD1G93A or SOD1G85R inhibited the
accumulation of misfolded SOD1 in a dose-dependent manner
(Figure 4F), consistent with an in vivo ability to suppress mutant
SOD1 accumulation onto microsomal (Figure 4B) or mitochon-
drial membranes (Figure 4C). Misfolding of SOD1G93A, which
can acquire normal folding (as indicated by dimerization, prote-
ase resistance, and high specific activity as a superoxide
dismutase; Borchelt et al., 1994; Ratovitski et al., 1999), was
more effectively suppressed by MIFC60S than was the dismutase
inactive SOD1G85R, most of which cannot adopt a stable confor-
mation that confers protease resistance (Figure 3E).
MIF Directly Suppresses the Accumulation of Misfolded
SOD1 In Vitro
To determine whether MIF directly inhibits the accumulation of
misfolded SOD1, immunoprecipitation was performed (see
schematic in Figure 5A) with a previously reported conforma-
tion-specific antibody (DSE2) that selectively recognizes mis-
folded, but not correctly folded, SOD1 (Israelson et al., 2010;
Vande Velde et al., 2008). As expected, a proportion of
SOD1G93A and SOD1G85R, but not SOD1WT, was immunoprecip-
itated with the DSE2 antibody (Figure 5B, lanes 3 and 5). Incuba-
tion of the mutant SOD1 with MIF nearly eliminated misfolded
SOD1G93A that could be immunoprecipitated by DSE2 (Fig-
ure 5B, lane 3 versus 4). MIF also substantially inhibited
accumulation of misfolded SOD1G85R (Figure 5B, lanes 5
and 6). Remarkably, a similar level of inhibition was observed
when the SOD1G85R mutant was incubated with a liver cytosolic
fraction that contained endogenous MIF accumulated to a
similar level (Figure 5B, lane 7).
Next, purified SOD1G93A was depleted of initially misfolded
SOD1 by immunoprecipitation with the B8H10 antibody (Fig-
ure 5D, lane 2), the unbound fraction free of misfolded SOD1
was incubated at 37C in the absence (lane 3) or presence
(lane 4) of MIF, and finally newly generated misfolded SOD1
was detected with a second round of immunoprecipitation with
the B8H10 antibody. Remarkably, MIF suppressed formation
of newly misfolded SOD1, as revealed by immunoblotting the
final immunoprecipitate (Figure 5D, lane 4). Suppression was
specific for MIF, because neither aB-crystallin nor Hsc70 (added
at comparable concentrations) inhibited formation of newly mis-
folded SOD1 (Figure S6).
Possible direct binding of MIF to mutant SOD1 was tested by
covalently labeling purifiedMIF with a green fluorescent dye (at a
ratio of one labeled lysine residue per one MIF molecule)
and incubating it with increasing concentrations of purified
SOD1G93A (2.4 nM to 80 mM). Binding of the two was quantified
using microscale thermophoresis, a sensitive protein-protein
interaction assay (Wienken et al., 2010) that measures changes
in the thermal migration behavior of particles in a temperature
gradient as influenced by a binding partner. By plotting the per-
centage of change in normalized fluorescence as a function of
SOD1G93A concentration (Wienken et al., 2010), curve fitting to
the data points produced an excellent fit with a calculated disso-
ciation constant (Kd) of 367 nM for interaction of mutant
SOD1G93A and MIF (Figure 5E).
A Low Level of Endogenous MIF within Motor Neuron
Perikarya
Immunostaining for MIF in nontransgenic rat spinal cord re-
vealed it to be accumulated widely, with the striking exception
of almost complete absence within choline acetyltransferase
(ChAT)-positivemotor neuron cell bodies (Figure 6A). In contrast,
MIF was readily detected in astrocytes (Figure 6B). Although no
change was apparent in overall MIF protein levels within the spi-nal cord during disease course (Figure S2), immunostaining
revealed increased MIF in reactive astrocytes just after symp-
tomatic onset (i.e., 1 week after the first fibrillation) in a SOD1G93A
rat (Figure 6D; Figure S7). Nevertheless, MIF protein remained
undetectable in motor neurons, and this low level of intraperi-
karyal MIF was accompanied by accumulation of misfolded
SOD1 (recognized by the B8H10 antibody) (Figures 6C and 6D;
arrows in Figure 6E; Figure S7).
To determine whether the absence of accumulatedMIF in mo-
tor neurons resulted from a low level (or absence) of synthesis of
MIF in those neurons, we exploited bacTRAP reporter mouse
lines (Doyle et al., 2008; Heiman et al., 2008) (see schematic in
Figure 7A) that express EGFP-tagged ribosomal protein L10a
(Rpl10a) driven by cell type-specific transgene promoters in
motor neurons (Chat-bacTRAP), astrocytes (Aldh1l1-bacTRAP),
or oligodendrocytes (Cnp1-bacTRAP) (Doyle et al., 2008; Hei-
man et al., 2008). Analysis of affinity-isolated, actively trans-
lating, polyribosome-associated mRNAs from each cell type
(Figure 7B) revealed that translating MIF mRNA was found in
all three cell types, with motor neurons accumulating the highest
level (Figure 7C). Thus, MIF is synthesized actively by motor
neurons, and its low accumulation in motor neuron cell bodies
(Figure 6) must be the result of rapid clearance (secretion, degra-
dation, or transport) from the perikarya of those neurons.
Increased MIF Enhances Survival of Mutant
SOD1-Expressing Motor Neurons
To test whether increased synthesis and accumulation of MIF
could be protective of mutant SOD1-expressing motor neurons,
motor neurons were isolated by fluorescence-activated cell sort-
ing (FACS) for expression of an HB9-promoted GFP motor
neuron reporter gene following differentiation from nontrans-
genic (non-Tg) mouse embryonic stem cells or induced pluripo-
tent stem cells (iPSCs) derived from mice expressing human
wild-type (SOD1WT) or mutant (SOD1G93A) SOD1 transgenes
(see schematic in Figure 8A). MIF synthesis was elevated by
transduction with a lentivirus (Lv) encoding MIF and red fluores-
cent protein (RFP) (the latter translated from an internal
ribosomal entry site in the MIF 30 UTR). Beginning day 3 post-
transduction, intraneuronal levels of MIF (detected by indirect
immunofluorescence with MIF antibody) were elevated relative
to motor neurons transduced with RFP alone (Figure 8B). The
contrast between the failure of endogenously synthesized MIF
to accumulate in mature motor neurons (Figure 6) and its
accumulation via lentiviral transduction in cultured motor
neurons (Figure 8) can be explained in two ways. Elevated MIF
synthesis in cultured motor neurons may saturate degrada-
tion or secretion machineries. Alternatively, the degradation/
secretion of endogenous MIF in mature motor neurons may
reflect a non-cell-autonomous influence, especially on secretion,
exercised by the partner glial cells, which are missing in our pure
neuronal cultures.
Direct live-cell imaging (Figure 8C) revealed that, compared to
nontransgenic or SOD1WTmotor neurons, only one-fifth as many
mutant SOD1G93A-expressing motor neurons survived the first
2 days of culture prior to MIF synthesis (Figures 8D–8F). MIF
expression, however, significantly attenuated this accelerated
motor neuron death at subsequent time points (Figure 8F).Neuron 86, 218–232, April 8, 2015 ª2015 Elsevier Inc. 223
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Figure 4. MIF Inhibits the Association of Misfolded Mutant SOD1 with Intracellular Membranes in a Cell-Culture Model of ALS
(A) Schematic of a protocol for assaying MIF-dependent inhibition of mutant SOD1 association in vivo with microsomes or mitochondria following expression of
MIF and SOD1G85R or SOD1G93A in motor neuron-like NSC-34 cells.
(legend continued on next page)
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Similarly, increased MIF significantly increased neurite length of
the surviving SOD1G93A motor neurons (Figure 8G).
DISCUSSION
Among the important unsolved questions in the disease
mechanism from ubiquitous expression of mutant SOD1 is
what determines the selective, age-dependent motor neuronal
degeneration that is accompanied by mutant SOD1 misfolding
and its association with mitochondria and the ER. We have
now determined that both dismutase active and inactive
SOD1 mutant association with such organelles can be
suppressed by cytosolic MIF acting catalytically to inhibit mis-
folded SOD1 accumulation and its association with mitochon-
dria and the ER. Furthermore, increased MIF, which normally
accumulates only to low levels within the cell bodies of motor
neurons, suppresses misfolded SOD1 accumulation and ex-
tends mutant SOD1-expressing motor neuron survival in cell
culture. The low level of MIF accumulated within motor neu-
rons correlates with accumulation of misfolded SOD1 species
and their association with different intracellular organelles
within those neurons.
Despite its small size (12 kDa), MIF has previously been impli-
cated in both extracellular and intracellular roles. MIF was one of
the first cytokines to be described (George and Vaughan, 1962),
with its action in the immune response upstream of tumor
necrosis factor-a, interleukin-1b, interferon-g, and other effector
cytokines (Calandra and Roger, 2003). MIF is synthesized as a
cytoplasmic protein (a point we have validated after removal of
even small vesicles from extracts of peripheral and nervous
system tissues; Figure 2E), with cytokine activity achieved by
posttranslational sequestration of cytoplasmic MIF into vesicles
for release by an as yet unidentified mechanism in response to a
variety of signals (Merk et al., 2009).
Intracellularly, MIF acts as a chaperone protein (Cherepkova
et al., 2006) and a thiol-protein oxidoreductase (Kleemann
et al., 1998). Its protein folding activity derives from switching
from multimeric to monomeric forms, thereby exposing a hydro-
phobic surface that can provide ATP-independent chaperone
activity. MIF’s multiple activities parallel the well-known ATP-
dependent protein chaperone Hsp70, for which dual roles as a
chaperone and cytokine have also been reported (Asea et al.,
2000; Pockley et al., 2009). The ability ofMIF to act as a thiol-pro-
tein oxidoreductase was initially of special interest to us for four
primary reasons. First, a major portion of misfolded SOD1 has
been proposed to be composed of SOD1 monomers lacking(B and C) Immunoblots for mutant SOD1 associatedwith (B) microsomes or (C) mi
or SOD1G85R and low or high levels of MIF. Parallel immunoblotting for calnexin
chondria, respectively. Similar immunoblot analyses of the initial cytosols were us
represent the means ± SEM of three independent experiments.
(D) Schematic of protocol to test whether expression of MIF, with or without i
misfolded mutant SOD1 within NSC-34 cells.
(E and F)MIF was expressed by transient transfection in NSC-34motor neuron-lik
SOD1 was detected by immunoblotting of immunoprecipitates produced with th
correctly folded SOD1. IP, immunoprecipitation.
(E) Expression of wild-type MIF.
(F) Expression of MIFC60S lacking thiol-oxidoreductase activity. MIF, endogeno
determined by immunoblotting in the unbound or initial cytosol fractions.the C57-C146 disulfide bond (Zetterstro¨m et al., 2013). Second,
mutant SOD1 proteins that associate with mitochondria have
been reported to be partially oxidized (Ferri et al., 2006), and
Cys-111 was reported to be necessary for mutant SOD1 associ-
ation with mitochondria (Cozzolino et al., 2008; Ferri et al., 2006).
Third, thiol-reductase activity has been proposed to reduce
oxidative stress and inhibit apoptosis (Nguyen et al., 2003).
Finally, overexpression of glutaredoxin-1 or glutaredoxin-2,
each with thiol-oxidoreductase activity, was reported to improve
the solubility of the mutant SOD1 and to prevent its mitochon-
drial binding (Cozzolino et al., 2008; Ferri et al., 2010). Neverthe-
less, using a MIF mutant that lacks all thiol-oxidoreductase
activity, we have demonstrated that it is the chaperone, not
thiol-oxidoreductase, activity of MIF that can inhibit mutant
SOD1 misfolding and membrane association.
We would also note that nearly eliminating aggregated mis-
folded SOD1 (by increasing mitochondrial buffering of calcium
by deletion of cyclophilin-D) has no effect on ameliorating fatal
disease progression in multiple SOD1 mutant mouse models
(Parone et al., 2013). Hence, rather than highly aggregated forms
as the toxic species, in vivo toxicity appears to derive from solu-
ble, misfolded SOD1, which remained unaffected in mice with
reduced aggregated mutant SOD1. This is the SOD1 species
that we have shown that MIF chaperone activity acts to reduce.
Other chaperones previously linked to SOD1, including Hsp27,
aB-crystallin, and Hsc70, were unable to suppress mutant
SOD1 binding to mitochondria or accumulation of newly formed
misfolded SOD1. From these collective efforts, we now propose
that lowMIF chaperone-like activity in alphamotor neurons plays
a pivotal role in misfolded SOD1 accumulation and subsequent
toxicity.
Of relevance to MIF’s extracellular activities, mutant SOD1
synthesized by microglia drives rapid disease progression
(Beers et al., 2006; Boille´e et al., 2006). Additionally, immuno-
deficiency shortened mutant SOD1 mouse lifespan (Beers
et al., 2008; Chiu et al., 2008) whereas, conversely, passive
transfer of activated T regulatory cells to immunocompetent
mice modestly extended survival (Beers et al., 2011). We note
that one of the manifestations of immune deficits in ALS could
be a malfunction of MIF, thereby leading to accumulation of
soluble misfolded SOD1 and binding to intracellular targets.
Indeed, recognizing the potential for cell-to-cell spread of mis-
folded SOD1 as a means of disease propagation (Grad and
Cashman, 2014; Grad et al., 2011; Mu¨nch et al., 2011),
chaperone activity by extracellular MIF may act to limit such
spreading.tochondria purified fromNSC-34 cells transfected to expressmutant SOD1G93A
or VDAC1 was used to verify comparable recovery of microsomes or mito-
ed to determine initial accumulated levels of MIF and mutant SOD1. Bar values
ts thiol-oxidoreductase activity, can act in vivo to suppress accumulation of
e cells also transfected to express wild-type or mutant human SOD1.Misfolded
e B8H10 antibody, which recognizes epitopes within exon 3 that are buried in
us SOD1, and EGFP-tagged wild-type or mutant human SOD1 levels were
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Figure 5. MIF SuppressesMisfoldedMutant
SOD1 Accumulation by Directly Acting on It
(A) Protocol to determine whether purified recom-
binant MIF suppresses accumulation of misfolded
SOD1 detectable with the DSE2 antibody, which
recognizes an epitope in the electrostatic loop of
hSOD1 (between residues 125 and 142) that is
buried in correctly folded SOD1.
(B) Accumulation of misfolded SOD1 was deter-
mined by immunoblotting of immunoprecipitates
with the DSE2 antibody after incubation of
recombinant hSOD1 wild-type, hSOD1G93A, or
hSOD1G85R (4 mg) in the absence or presence of
recombinant MIF (100 ng). Immunoblotting was
used to determine MIF levels remaining in the
unbound fraction of each immunoprecipitation
assay.
(C) Protocol to determine whether purified re-
combinant MIF suppresses accumulation of newly
formed, misfolded SOD1 detectable with the
B8H10 antibody for misfolded SOD1.
(D) Misfolded SOD1 determined by immunoblot-
ting of immunoprecipitates of recombinant
hSOD1G93A with the B8H10 antibody (lane 1). The
unbound fraction was subjected to a second
immunoprecipitation performed immediately
(lane 2) or after a 5-hr incubation in the (lane 3)
absence or (lane 4) presence of recombinant MIF.
Immunoblotting was also used to determine MIF
levels remaining in the unbound fraction of each
immunoprecipitation assay.
(E) Assay of MIF binding to mutant SOD1. Purified
MIF (200 nM) was fluorescently labeled and
incubated for 20 min at room temperature with
increasing concentrations (from 2.4 nM to 80 mM)
of SOD1G93A. Closed diamonds indicate binding
of MIF to SOD1G93A determined by microscale
thermophoresis assay. The smooth curve repre-
sents the predicted binding of MIF to mutant
SOD1 calculated by curve fitting with a Kd of
367 nM (see Jerabek-Willemsen et al., 2011;
Parker and Newstead, 2014; Wienken et al.,
2010).Finally, misfolded SOD1 has been reported by several groups
to accumulate in motor neurons or glia in sporadic ALS (Bosco
et al., 2010; Forsberg et al., 2010, 2011; Grad et al., 2014; Guar-
eschi et al., 2012; Kabashi et al., 2007; Pokrishevsky et al., 2012;
Zetterstro¨m et al., 2011a), although other efforts have reached
opposite conclusions (Ayers et al., 2014; Brotherton et al.,
2012; Kerman et al., 2010; Liu et al., 2009). Astrocytes generated
from neuronal progenitor cells (NPCs) isolated from spinal cords
of sporadic ALS patients have been found to be toxic to cocul-
tured motor neurons (Haidet-Phillips et al., 2011), similar to
what had been seen previously for astrocytes expressing mutant
SOD1 (Di Giorgio et al., 2007; Marchetto et al., 2008; Nagai et al.,
2007). Surprisingly, reducing wild-type SOD1 with small hairpin
RNA significantly reduced toxicity to motor neurons of most of
the ‘‘sporadic’’ ALS astrocytes (Haidet-Phillips et al., 2011), a
finding directly disputed by others who concluded that wild-226 Neuron 86, 218–232, April 8, 2015 ª2015 Elsevier Inc.type SOD1 plays no role in the toxicity of sporadic ALS-derived
astrocytes to cocultured motor neurons (Re et al., 2014).
The controversy notwithstanding,misfolded protein accumula-
tion is central to essentially all instances of inherited and sporadic
ALS. Identification of MIF as an intracellular chaperone that stim-
ulates folding/refolding of misfolded SOD1 suggests a new
avenue for therapy development in ALS through increasing intra-
cellular MIF levels. Combined with recognition that extracellular
MIF is an inducer of metalloproteinase 9 (MMP9) (Yu et al.,
2007), a component contributing to theselectivity ofmotor neuron
vulnerability to SOD1 mutant-mediated death (Kaplan et al.,
2014), this finding underscores how approaches to increasing
intracellular MIF (e.g., by reducing its clearance from motor neu-
rons) and/or to inhibiting its induction of MMP9 (e.g., with drugs
that block MIF’s interaction with its known receptor [CD74; Bai
et al., 2012]) could be attractive therapeutic strategies.
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Figure 6. A Low Level of MIF in Motor Neuron Cell Bodies Is Accompanied by Diffuse Accumulation of Misfolded SOD1 within Those Cell
Bodies Just after Disease Onset in SOD1G93A Rats
(A) Accumulation of MIF in lumbar spinal cord of a nontransgenic rat assayed by indirect immunofluorescence with antibodies to MIF along with simultaneous
identification of motor neurons (with antibodies to ChAT) and misfolded SOD1 (with the B8H10 antibody).
(B) An analogous assay as in (A) but with astrocytes identified with an antibody to glial fibrillary acidic protein (GFAP).
(C) Accumulation of MIF in lumbar spinal cord of an early symptomatic SOD1G93A rat, 1 week after the first spontaneous muscle fibrillation, along with simul-
taneous identification of motor neurons (identified by morphology, position, and antibodies to NeuN) and misfolded SOD1 (with the B8H10 antibody).
(D) An analogous assay as in (C) but with astrocytes identified with an antibody to GFAP. The scale bar represents 50 mm.
(E) Higher magnification of the insets outlined in (D). The arrows highlight a motor neuron lacking MIF immunostaining, and asterisks mark GFAP-positive
astrocytes containing MIF.
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Figure 7. Translational mRNA Levels of MIF in Specific Cell Types in
Mouse Spinal Cord
(A) Schematic of the bacTRAP methodology for isolating cell type-specific
translated mRNAs.
(B) Relative RNA levels (assessed by qRT-PCR) of cell type-specificmarkers to
test the efficacy of polysome-associated RNApurification frommotor neurons,
astrocytes, and oligodendrocytes.
(C) Relative MIF RNA level (assayed by qRT-PCR) of polysomal RNAs isolated
from motor neurons, astrocytes, and oligodendrocytes. Levels are normalized
to Dnaja2.
Error bars represent SEM from three or four biological replicates.
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Transgenic Animals
Transgenic rats expressing hSOD1WT (Chan et al., 1998), hSOD1G93A (How-
land et al., 2002), and hSOD1H46R (Nagai et al., 2001) were as originally
described. Transgenic mice expressing mutant SOD1G85R (line 148),
SOD1G37R (line 42), or SOD1G93A were maintained by standard protocols in
the D.W.C. laboratory. bacTRAP transgenic mouse lines: Chat-bacTRAP line
expresses EGFP-tagged ribosome protein Rpl10a only within motor neurons.
The Aldh1l1-bacTRAP line expresses the same EGFP-tagged Rpl10a in astro-
cytes, whereas theCnp1-bacTRAP line expresses in mature oligodendrocytes
(Doyle et al., 2008; Heiman et al., 2008). All animal procedures were consistent
with the requirements of the Animal Care and Use Committees of the Univer-
sity of California and Ben-Gurion University of the Negev.
Mutant SOD1 Binding to Mitochondria
Spinal cord or liver cytosolic fractions (200 mg) from hSOD1G93A (90-d-old) or
hSOD1H46R (200-d-old) symptomatic female rats or recombinant hSOD1WT,
hSOD1G93A, or hSOD1G85R proteins (4 mg) were incubated with spinal cord or
liver mitochondria (50 mg) isolated from nontransgenic rats for 30min at 37C in
the presence or absence of recombinant mouse MIF (R&D Systems) at the
indicated concentration. Where indicated, recombinant mutant SOD1 was
incubated with proteinase K (100 mg/ml) for 15 min. The reaction was stopped
by addition of 10mMPMSF followed by incubation on ice for 10min. Then, the
mitochondrial fraction was recovered by centrifugation at 12,000 3 g for
10 min at 4C and washed twice with mitochondrial buffer. The pellet was re-
suspended with sample buffer and run on SDS-PAGE.
iPSC Generation
Neuronal progenitor cells expressing the motor neuron HB9::GFP reporter ob-
tained from SOD1WT and SOD1G93A mice were converted to iPSCs. As previ-
ously described, retrovirus encoding OCT3/4 and KLF4 was sufficient to
generate iPSC clones (Hester et al., 2009; Kim et al., 2008). Twenty viral parti-
cles per cell were needed to efficiently reprogram the cells. Cells were cultured
in the presence of NPC media for 4 days followed by a change to mouse em-
bryonic stem cell (mESC) media with DMEM (Millipore), supplemented with ES
fetal bovine serum (18%; Invitrogen), L-glutamine (2 mM; Invitrogen), nones-
sential amino acids (13; Millipore), antibiotic-antimycotic (1%; Invitrogen),
2-mercaptoethanol (114 mM; Sigma), and recombinant LIF (100 U/ml; Milli-
pore). iPSC clones were morphologically similar to mouse ESCs (HBG3 cells;
Thomas Jessell, Columbia University) and were obtained within 2 weeks. A
wide panel of markers was used to compare ESCs with the newly generated
iPSC lines and found no significant difference in their expression between
cell lines.
Mouse Motor Neuron Differentiation
Mouse ESCs or iPSCs expressing HB9::GFP reporter were cultured on top
of inactivated mouse fibroblasts (Millipore). Motor neuron differentiation
was induced by plating 1–2 3 106 mES cells per 10-cm dish in the pres-
ence of 2 mM retinoic acid (Sigma-Aldrich) and 2 mM purmorphamine (Calbio-
chem). After 5 days of differentiation, embryonic bodies were dissociated
and sorted based on levels of GFP using a FACSVantage/DiVa sorter (BD
Biosciences).
Expression of MIF in Mouse Motor Neurons and Analysis
To express MIF in motor neurons, a previously described protocol was fol-
lowed with minor modifications (Kaech and Banker, 2006). Briefly, sorted
GFP+motor neurons were plated at a density of 15,000 cells per well on a lam-
inin-coated 96-well plate. Twelve hours after plating, the cells were infected
with lentivirus to overexpress transgenes (40 viral particles per motor neuron).
Motor neuron cultures were allowed to continue for another 5 days, with half of
the media being replaced every other day. RFP could be detected after 72 hr
postinfection. At various time points during the culture of motor neurons,
images were recorded using a fully automated IN Cell 6000 cell imager (GE
Healthcare) as previously reported (Meyer et al., 2014). Images were further
processed with the Developer and Analyzer software package (GEHealthcare)
for survival counts and neurite length measurements. Unless otherwise noted,
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Figure 8. Increased Accumulation of MIF Enhances Survival of Primary Motor Neurons Expressing Mutant SOD1
(A) Protocol for generating motor neurons and assaying effects of MIF expression.
(B) Representative images of motor neuron cultures at 96 hr postinfection with Lv-RFP or Lv-MIF-RFP and using immunocytochemistry to reveal humanMIF and
RFP in motor neurons.
(C–F) Viability of GFP+RFP+ nontransgenic, SOD1WT, and SOD1G93A motor neurons (MNs) (C) imaged at 5 days or (D–F) quantified from images taken from 3 to
5 days after transduction with lentivirus encoding RFP or MIF and RFP. Data are representative of three independent experiments and are displayed as the
mean ± SEM counts of triplicate wells. Two-way ANOVA was used for statistical analysis. *p < 0.05; **p < 0.01; ****p < 0.0001; n.s, nonsignificant.
(G) Neurite length measurements quantified from images as in (C) taken at day 5. Data show a representative example of two independent experiments and
are displayed as the median with range. One hundred neurites per condition were included for measurements. Student’s t test was used for statistical analysis.
**p < 0.01; n.s, nonsignificant.images shown represent 120 hr postinfection. All counts were performed in
triplicate and repeated at least three times.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
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